3 results
1. Primary objective:To evaluate whether subcutaneous immunoglobulin infusion is as effective as intravenous immunoglobulin in maintaining muscle strength in patients with multifocal motor neuropathy.2. Secondary objective:a) To evaluate whether…
The sponsor is developing a biological product (DRL_AB) similar to the approved medicine Orencia®. As part of medical-scientific studies to confirm the similarity of the biological products, the Sponsor wants to compare DRL_AB with EU-approved…
To find a suitable treatment option for the 25% of HS patients who are therapy-resistant. Additionally, we expect a faster healing time of the wounds, meaning that even if patients respond to current treatment, HBOT may improve their quality of life…